JUPITER NEUROSCIENCES, INC. (JUNS): Nasdaq/NYSE listing notice — Jupiter Neurosciences receives Nasdaq delisting notice for bid price non-compliance

JUPITER NEUROSCIENCES, INC.

Nasdaq notified JUNS on Mar 21, 2025 that bid price closed below $1.00 for 30 consecutive business days through Mar 20, 2025.
Company has 180 calendar days, until Sept 17, 2025, to regain compliance by closing at $1.00 or higher for 10 consecutive days.
No immediate impact on listing; stock continues trading on Nasdaq; company may consider options to cure the deficiency.
If compliance not regained by Sept 17, JUNS may be eligible for additional time or face delisting.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

JUPITER NEUROSCIENCES, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

March 21, 2025, Jupiter Neurosciences, Inc. (the “Company”) received a letter (the “Notice”) from the Nasdaq Stock Market LLC (the “NASDAQ”) notifying the Company that it is not in compliance with the minimum bid price requirement as set forth under NASDAQ Listing Rule 5550(a)(2) for continued listing of its common stock on the NASDAQ. Listing Rule 5550(a)(2) requires the registrant to maintain a minimum bid price of $1.00 USD per share for its securities listed on the NASDAQ, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficie

View on SEC.gov

Browse all listing & compliance notices →

JUPITER NEUROSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001641172-25-000627

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.